Company Overview - Whitehawk Therapeutics, Inc. is an oncology therapeutics company focused on applying advanced technologies to established tumor biology for improved cancer treatments [2] - The company has developed a three-asset ADC portfolio designed to address the limitations of first-generation therapies, aiming to significantly impact patients with difficult-to-treat cancers [2] Upcoming Events - The company's president and CEO, Dave Lennon, PhD, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, at 4:50 PM ET [4] - Additionally, he will engage in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 3:30 PM ET [4] - Live webcasts of these events will be available on the Whitehawk Therapeutics IR website and can be replayed for approximately 30 days post-event [1]

Core Insights - Whitehawk Therapeutics, Inc. is an oncology therapeutics company focused on advanced technologies to enhance ADC cancer treatments [1][2] - The company will participate in the BTIG Virtual Biotechnology Conference on July 29-30, 2025 [1] Company Overview - Whitehawk Therapeutics specializes in oncology therapeutics, utilizing advanced technologies to improve cancer treatment delivery [2] - The company has developed a three-asset ADC portfolio designed to address the limitations of first-generation treatments, aiming to significantly benefit patients with challenging cancers [2] - These assets are exclusively licensed from WuXi Biologics under a global commercialization agreement [2]